Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

Summary

This is a randomized, dose-ranging, efficacy and tolerability study in chronic kidney disease patients with hyperphosphatemia on hemodialysis. Patient participation in the study is approximately 10 weeks in duration.

Timeline

Start

2006-06

Primary completion

—

Completion

—

Drugs

Indications